Vicore Pharma Holding AB (STU:6Y4) Cyclically Adjusted PB Ratio: (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6Y4 Vicore Pharma Holding AB STU:6Y4
30 GF Score
Price €0.99
! 2 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Vicore Pharma Holding AB  (STU:6Y4) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Related Terms


Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Chart

Vicore Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.36 1.89

Vicore Pharma Holding AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.24 2.20 1.89 1.70 0.00

STU:6Y4 vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio falls into.


STU:6Y4
30GF Score
Vicore Pharma Holding AB STU:6Y4
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vicore Pharma Holding AB's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Vicore Pharma Holding AB's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.277/134.6100*134.6100
=0.277

Current CPI (Jun. 2026) = 134.6100.

Vicore Pharma Holding AB Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.558 101.138 0.743
201612 0.225 102.022 0.297
201703 0.576 102.022 0.760
201706 0.670 102.752 0.878
201709 0.674 103.279 0.878
201712 0.312 103.793 0.405
201803 0.621 103.962 0.804
201806 0.641 104.875 0.823
201809 0.479 105.679 0.610
201812 0.820 105.912 1.042
201903 0.612 105.886 0.778
201906 0.548 106.742 0.691
201909 0.497 107.214 0.624
201912 0.595 107.766 0.743
202003 0.526 106.563 0.664
202006 0.502 107.498 0.629
202009 0.636 107.635 0.795
202012 0.561 108.296 0.697
202103 0.839 108.360 1.042
202106 0.749 108.928 0.926
202109 0.617 110.338 0.753
202112 0.506 112.486 0.606
202203 0.375 114.825 0.440
202206 0.291 118.384 0.331
202209 0.201 122.296 0.221
202212 0.313 126.365 0.333
202303 0.238 127.042 0.252
202306 0.277 129.407 0.288
202309 0.417 130.224 0.431
202312 0.355 131.912 0.362
202403 0.376 132.205 0.383
202406 0.336 132.716 0.341
202409 0.290 132.304 0.295
202412 0.419 132.987 0.424
202503 0.397 132.825 0.402
202506 0.352 133.699 0.354
202509 0.309 133.480 0.312
202512 0.358 133.390 0.361
202603 0.327 133.560 0.330
202606 0.277 134.610 0.277

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vicore Pharma Holding AB Business Description

Other Exchanges VICO:Sweden
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
30GF Score

Get the complete analysis for STU:6Y4

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.99
Price